Pharmacokinetics, Safety Issues
Conditions
Brief summary
This is a single and multiple dose, parallel group study to assess safety and pharmacokinetics of oral HTL0018318 in healthy Japanese and Caucasian subjects.
Detailed description
This is a single and multiple dose, parallel group study to assess safety and pharmacokinetics of oral HTL0018318 in healthy Japanese and Caucasian subjects. The study will be conducted in two parts: (A) single doses of HTL0018318 in healthy, adult, male Caucasian and Japanese subjects; (B) multiple doses of HTL0018318 in healthy, adult, male Caucasian and Japanese subjects.
Interventions
DRUGHTL0018318
Part A single dose Part B five doses
DRUGPlacebo oral capsule
Part B only
Sponsors
Nxera Pharma UK Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Part A open label, Part B double blind.
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male subjects, either Caucasian or Japanese aged ≥20 and ≤40 years. 2. Japanese subjects must have lived outside of Japan for ≤ 5 years in total and be first generation Japanese, defined as born in Japan and having 4 biologic grandparents who are ethnic Japanese. 3. The Caucasian subjects should be distinguished especially by very light to brown skin pigmentation and straight to wavy or curly hair, and should be indigenous to Europe, northern Africa and western Asia. Therefore, the study may include Caucasian subjects from North America, New Zealand, Australia and South Africa. 4. Subjects must have a body mass index (BMI) between 18.0-25.0 kg/m² inclusive. 5. Male subjects, if heterosexually active and with a female partner of childbearing potential or a pregnant or breastfeeding partner, must agree to use barrier contraception (male condom) for the treatment period and for at least 3 months after the end of the systemic exposure of the study drug. 6. Satisfactory medical assessment with no clinically significant or relevant abnormalities. 7. Able to perform spirometry/peak flow with a satisfactory technique at screening. 8. Ability to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the International Council of Harmonization Good Clinical Practice (GCP) Guideline E6. 9. An understanding, ability, and willingness to fully comply with study procedures and restrictions
Exclusion criteria
1. Any history of any condition associated with cognitive impairment, including but not limited to schizophrenia and dementia. 2. History of epilepsy or seizures of any kind at any time. 3. Current or relevant history of any physical or psychiatric illness that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures. 4. The history or presence of any of the following cardiac conditions: known structural cardiac abnormalities; family history of long QT syndrome; cardiac syncope or recurrent, idiopathic syncope; exercise related clinically significant cardiac events. 5. Presence or history of drug or alcohol abuse in the last 5 years, or the inability to refrain from alcohol use from 48 hours before screening, dosing and each scheduled visit until the end of the study. 6. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch, electronic cigarettes) within 3 months prior to the planned first day of dosing. 7. Use of prescription medications within 14 days or 10 half-lives (whichever is longer) prior to Day 1 of the dosing period, or any over-the-counter (OTC) medication (including multivitamin, herbal, or homeopathic preparations, excluding hormonal contraception, hormone-replacement therapy, and/or an occasional dose of acetaminophen) within 7 days prior to Day 1 of the dosing period. 8. History of significant allergic reaction (anaphylaxis, angioedema) to any product (food, pharmaceutical, etc). 9. Has donated or lost 400 mL blood or more within the last 16 weeks preceding the first day of dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | Baseline to 72 hours | Comparison of pharmacokinetics in plasma |
| Tmax | Baseline to 72 hours | Comparison of pharmacokinetics in plasma |
| Area under the curve | Baseline to 72 hours | Comparison of pharmacokinetics in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Amount excreted in urine | Baseline to 72 hours | Pharmacokinetics in urine |
| Fraction of dose eliminated unchanged in urine (fe/F) | Baseline to 72 hours | Pharmacokinetics in urine |
| Treatment emergent adverse events (TEAEs) | Up to 14 day post dose | Safety and tolerability |
| Number of participants with abnormal physical exam results | Up to 14 day post dose | Safety and tolerability |
| Delay in absorption (Tlag) | Baseline to 72 hours | Pharmacokinetics in plasma |
| Number of participants with abnormal laboratory values | Up to 14 day post dose | Safety and tolerability |
| ECG | Up to 14 day post dose | Safety and tolerability |
| Blood pressure | Up to 14 day post dose | Safety and tolerability |
| Heart Rate | Up to 14 day post dose | Safety and tolerability |
| Rate of elimination | Baseline to 72 hours | Pharmacokinetics in plasma |
| Half life (t1/2) | Baseline to 72 hours | Pharmacokinetics in plasma |
Countries
United Kingdom
Outcome results
None listed